Brii Biosciences Limited Stock

Equities

2137

KYG1645A1094

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 04:08:22 2024-05-10 am EDT 5-day change 1st Jan Change
1.26 HKD -3.08% Intraday chart for Brii Biosciences Limited -8.03% -44.74%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2023 417M 57.69M 451M Sales 2024 * - Capitalization 850M 118M 919M
Net income 2023 -175M -24.22M -189M Net income 2024 * -575M -79.59M -622M EV / Sales 2023 2.46 x
Net cash position 2023 486M 67.34M 526M Net cash position 2024 * 956M 132M 1.03B EV / Sales 2024 * -
P/E ratio 2023
-8.63 x
P/E ratio 2024 *
-1.54 x
Employees 128
Yield 2023 *
-
Yield 2024 *
-
Free-Float 80.49%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Brii Biosciences Limited

1 day-3.08%
1 week-8.03%
Current month+0.80%
1 month+28.57%
3 months-28.00%
6 months-55.48%
Current year-44.74%
More quotes
1 week
1.23
Extreme 1.23
1.41
1 month
0.85
Extreme 0.85
1.43
Current year
0.85
Extreme 0.85
2.39
1 year
0.85
Extreme 0.85
4.24
3 years
0.85
Extreme 0.85
52.60
5 years
0.85
Extreme 0.85
52.60
10 years
0.85
Extreme 0.85
52.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 17-12-07
Director of Finance/CFO 47 20-08-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 58 21-06-21
Director/Board Member 70 22-08-31
Director/Board Member 60 18-06-21
More insiders
Date Price Change Volume
24-05-10 1.26 -3.08% 2,809,500
24-05-09 1.3 +1.56% 2,983,500
24-05-08 1.28 0.00% 1,389,500
24-05-07 1.28 +0.79% 1,990,000
24-05-06 1.27 -7.97% 2,814,000

Delayed Quote Hong Kong S.E., May 10, 2024 at 04:08 am EDT

More quotes
Brii Biosciences Ltd is a biotechnology company based in China and the United States principally engaged in developing therapies for infectious diseases. The Company’s products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The Company is also developing therapies for COVID-19 and other diseases.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.165 CNY
Average target price
4.314 CNY
Spread / Average Target
+270.22%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW